Opening book details…
About this Medicine article
Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations by Creelan, B C; Yeh, T; Kim, S-W; Nogami, N; Kim, D-W; Chow, L Q; Kanda, S; Taylor, R; Tang, W; Tang, M; Angell, H K; Roudier, M P; Marotti, M; Gibbons, D L is a Medicine article available to read on EtoBox.
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Creelan, B C; Yeh, T; Kim, S-W; Nogami, N; Kim, D-W; Chow, L Q; Kanda, S; Taylor, R; Tang, W; Tang, M; Angell, H K; Roudier, M P; Marotti, M; Gibbons, D L
- Publisher
- Oxford University Press; Elsevier BV (ISSN 0923-7534)
- Published
- 2019
- Field
- Medicine (Health Sciences)